Imugene thrilled as first patient dosed in Phase 1 OASIS trial

Cloud PRWire

–News Direct–

Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company has marked a milestone with the start of its Phase 1 clinical trial for onCARlytics, a CD19 oncolytic virotherapy drug candidate. The trial, known as OASIS (Oncolytic Assessment and Safety in Solid Tumours), represents a world-first in clinical research, combining CD19 oncolytic virotherapy with a CD19 targeting bispecific monoclonal antibody, blinatumomab (Blincyto Amgen). The primary objective of the OASIS trial is to assess the safety and tolerability of onCARlytics (CF33-CD19) when administered intravenously or intratumorally in combination with blinatumomab.

Chong said: This is a milestone weve been eagerly anticipating, given the encouraging signs we have seen from the pre-clinical work performed to date.

We believe onCARlytics may provide a new solution for clinicians treating solid tumours that have previously been untreatable using CD19-targeting biological drugs, and we hope our technology can bring much needed relief to patients in want of new treatments.

I am particularly pleased with the speed at which our team drove the pre-clinical data from a novel therapy, into a Phase 1 trial in a little over two years, and reflects the enthusiasm for this promising therapy, from all involved.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

View source version on

Imugene Ltd

comtex tracking